º£½ÇÉçÇø

Greg Korbutt is the Scientific Director of the Alberta Cell Therapy Manufacturing Facility. The main objective of his research is the development of a more accessible source of insulin-producing tissue for transplantation into patients with type 1 diabetes. To address the shortage problem, Dr. Korbutt’s research group has taken the approach of using neonatal porcine islets as a potential source of islets for clinical transplantation. His lab also focuses on transplanting insulin producing cells without the need for using toxic antirejection drugs.